Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3775

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3775 9)

The label is for Duloxetine 60 mg delayed-release capsules, packaged by NuCare Pharmaceuticals, Inc. and manufactured by Lupin Limited Goa. It shows an NDC of 68071-3775-9 for a 90-capsule quantity. The label includes dosing instructions, warnings to keep out of reach of children, and storage conditions at 68-77°F. Additional identification details such as lot number, expiration date, and serial number appear on the right side.*

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Chemical structure of duloxetine hydrochloride, showing the compound's aromatic rings, oxygen, sulfur atoms, and methylated amine hydrochloride group in a 2D bond-line formula diagram.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

A Kaplan-Meier estimator graph depicting the proportion of patients with relapse over time (days) from randomization. The chart compares two treatments: Placebo (dashed line) and Duloxetine (solid line). The y-axis shows the proportion of patients with relapse from 0 to 1, and the x-axis shows time in days up to 250.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

A Kaplan-Meier survival curve chart depicting the proportion of patients with relapse over time (days) from randomization. The chart compares two treatments: Duloxetine and placebo, showing relapse proportions on the y-axis and time in days on the x-axis up to 300 days. Duloxetine is represented by a solid line and placebo by a dashed line.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares effectiveness of different Duloxetine dosages and placebo in pain improvement across a continuum from 0% to 100% pain improvement.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph shows trends in pain improvement across these groups with percent improvement on the x-axis and percentage of patients improved on the y-axis.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline, comparing Duloxetine 60 mg taken once daily, Duloxetine 60 mg taken twice daily, and placebo groups. The graph illustrates patient response distributions across varying levels of pain improvement percentages.*

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. The graph compares Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 60 mg once daily (different data), and placebo groups, illustrating patient improvement percentages across various pain improvement thresholds.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

A line graph depicting the percentage of pediatric patients aged 13 to 17 with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines compare Duloxetine 60 mg once daily versus placebo, with Duloxetine showing higher percentages of patients improved across varying pain relief levels.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF) comparing placebo and Duloxetine 60/120 mg once daily. Two lines illustrate patient improvement trends, with the Duloxetine group consistently showing higher improvement percentages across various pain improvement levels.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The graph shows two lines representing patient improvement rates across varying pain improvement thresholds, with Duloxetine generally showing higher improvement percentages than placebo.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The graph shows two lines, one for placebo marked with crosses and another for Duloxetine marked with diamonds, indicating patient improvement percentages across various pain improvement thresholds from greater than 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.